Tests prasinezumab infusions against placebo in early Parkinson's disease
Tests prasinezumab, given into a vein, in adults with early-stage Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Key facts
- Where
- Albuquerque, Amherst, Asheville, Atlanta, Atlantis, Birmingham, Boca Raton, Boston, Burlington, Canton, Charlottesville, Chicago, Cleveland, Commack, Dallas, Durham, Englewood, Farmington Hills, Fullerton, Honolulu, Kansas City, La Jolla, Lady Lake, Las Vegas, Los Angeles, Maitland, Memphis, Miami, Morgantown, Nashville, New Haven, New York, Orlando, Palo Alto, Paramus, Pasadena, Philadelphia, Phoenix, Pittsburgh, Portland, Reno, Richmond, Round Rock, San Francisco, Sioux Falls, St Louis, Stanford, Tampa, Tulsa, and Washington D.C., United StatesSee the 53 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
- Has a doctor told you that you have a different condition with similar signs, such as multiple system atrophy or progressive supranuclear palsy?
- Which medicine do you take for Parkinson's disease now?
- Are you pregnant, breastfeeding, or planning a pregnancy?
Source: NCT07174310, who can take part
Where in United States
- University of New MexicoAlbuquerque, United StatesTaking people
- Dent Neurological InstituteAmherst, United StatesTaking people
- Asheville NeurologyAsheville, United StatesTaking people
- Grady Memorial HospitalAtlanta, United StatesTaking people
- JEM Research LLCAtlantis, United StatesTaking people
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- Parkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- University of Vermont Medical CenterBurlington, United StatesTaking people
- NeuroCare CenterCanton, United StatesTaking people
- University of Virginia Health SystemCharlottesville, United StatesTaking people
- Northwestern University Feinberg School of MedicineChicago, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- Parkinson's Research Centers of America - Long IslandCommack, United StatesTaking people
- Texas Neurology, PADallas, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- Rocky Mountain Movement DisordersEnglewood, United StatesTaking people
- QUEST Research InstituteFarmington Hills, United StatesTaking people
- Neurology Center of North Orange CountyFullerton, United StatesTaking people
- Hawaii Pacific NeuroscienceHonolulu, United StatesTaking people
- University of Kansas Medical CenterKansas City, United StatesTaking people
- UC San DiegoLa Jolla, United StatesTaking people
- K2 - VillagesLady Lake, United StatesTaking people
- Cleveland Clinic Lou RuvoLas Vegas, United StatesTaking people
- Keck School of Medicine of USCLos Angeles, United StatesTaking people
- UCLA Neurology Outpatient ClinicLos Angeles, United StatesTaking people
- K2 Medical Research - MaitlandMaitland, United StatesTaking people
- Veracity NeuroscienceMemphis, United StatesTaking people
- Baptist Hospital of MiamiMiami, United StatesTaking people
- West Virginia UniversityMorgantown, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Institute for Neurodegenerative DisordersNew Haven, United StatesTaking people
- Columbia University Medical CenterNew York, United StatesTaking people
- Weill Cornell Medical CollegeNew York, United StatesTaking people
- Advent Health OrlandoOrlando, United StatesTaking people
- Charter Research - Winter Park/OrlandoOrlando, United StatesTaking people
- Parkinson?s Research Centers of America ? Palo AltoPalo Alto, United StatesTaking people
- Hackensack University Medical Center;Department of Neurology, Neuroscience InstituteParamus, United StatesTaking people
- Profound Research LLC at The Neurology Center of Southern CaliforniaPasadena, United StatesTaking people
- University Pennsylvania HospitalPhiladelphia, United StatesTaking people
- Barrow Neurological InstitutePhoenix, United StatesTaking people
- Allegheny General HospitalPittsburgh, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- Renown HealthReno, United StatesTaking people
- VCU Health North HospitalRichmond, United StatesTaking people
- Central Texas Neurology ConsultantsRound Rock, United StatesTaking people
- UCSF Weill Institute for NeurosciencesSan Francisco, United StatesTaking people
- Avera Medical GroupSioux Falls, United StatesTaking people
- Washington Uni School of MedicineSt Louis, United StatesTaking people
- Stanford Neuroscience Health Center (SNHC)Stanford, United StatesTaking people
- USF Parkinsons Disease and Movement Disorders CenterTampa, United StatesTaking people
- The Movement Disorder Clinic of OklahomaTulsa, United StatesTaking people
- Georgetown UniversityWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07174310EU 2025-522683-32-00
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Inclusion: Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2; Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria; Has received monotherapy treatment; An MDS-UPDRS Part IV score of 0 at screening and prior to randomization; Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization; Agreement to adhere to the contraception requirements.
Exclusion: Medical history indicating a parkinsonian syndrome other than idiopathic PD; Diagnosis of a significant neurologic disease other than PD; Chronic uncontrolled hypertension; Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required.